GlassScriptPhysician profile
Michael John Scanameo
NPI 1205819331
$9,166.12
in general payments reported to CMS, 2019-2025
32 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,484 · 2020: $318 · 2021: $1,229 · 2022: $467 · 2023: $1,081 · 2024: $1,403 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,650 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,650.32 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,593.56 | 2019-2021 | |
| Glaukos Corporation | $1,072.40 | 2019-2025 | Idose, Istent Infinite, Iaccess Precision Blade |
| Alcon Vision LLC | $792.40 | 2019-2025 | Hydrus Microstent, Tryptyr, Eysuvis |
| Johnson & Johnson Surgical Vision, INC. | $409.16 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Rxsight INC | $384.51 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $303.79 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $286.22 | 2022-2025 | Miebo, Envista Mx60 Iol, Ic-8 Apthera Iol |
| Harrow Eye, LLC | $282.14 | 2023 | Iheezo |
| Abbvie INC. | $225.86 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $198.18 | 2019-2025 | |
| Coopervision INC. | $189.82 | 2023-2025 | Myday Contact Lens, Clariti Contact Lens |
| Mallinckrodt Hospital Products INC. | $181.73 | 2021 | |
| Biotissue Holdings INC. | $167.08 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $158.58 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $134.31 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $118.85 | 2021-2024 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Maculogix, INC. | $108.12 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $80.99 | 2019-2021 | |
| Amgen INC. | $71.43 | 2025 | Tepezza |
| Eyepoint US, INC. | $62.08 | 2019-2021 | |
| Dompe US, INC. | $49.04 | 2025 | Oxervate |
| Ivantis, INC | $43.54 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $40.00 | 2021 | |
| Alimera Sciences, INC. | $35.80 | 2020 | |
| Shire North American Group INC | $32.11 | 2019 | |
| Horizon Therapeutics Plc | $27.73 | 2021 | |
| Apellis Pharmaceuticals, INC. | $26.57 | 2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $22.27 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $19.89 | 2021 | |
| Astellas Pharma US INC | $18.01 | 2024 | Izervay |
| Thea Pharma INC. | $17.95 | 2023 | |
| Lensar, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Scanameo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.